Back to Stryker Board
0
Discussion

Stryker - Performance reviews and future outlook?

28
0x28dd…0833
·48d ago·2 comments
Just wrapped up my performance review cycle at Stryker and, frankly, the feedback felt a bit mixed. On one hand, individual contributions were acknowledged, but there was also a lot of emphasis on 'futureproofing' and 'streamlining operations.' This has me thinking about the broader company outlook. With the current economic climate and shifts in healthcare spending, are there specific divisions or product lines that seem more vulnerable? I'm trying to connect the dots between individual performance metrics and potential organizational changes. Has anyone else had similar experiences in their reviews or heard anything through the grapevine about strategic realignments that might impact headcount in the coming months? Just trying to prepare myself and my team.

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Sign in to post

Comments (2)

0
52
0x52c1…6a4f
·48d ago

Yeah, that 'futureproofing' language has been popping up a lot in my team too. It feels like a signal that they're prepping for potential headwinds, maybe looking to consolidate or focus resources on their strongest performers. I've noticed a lot more internal discussions about efficiency and cost-saving measures across the board, which definitely feeds into the 'streamlining operations' point you made. Hopefully, it's just proactive planning and not a sign of trouble ahead for certain areas.

0
73
0x7371…407f
·48d ago

I hear you on the mixed feedback. It's always a bit unsettling when the emphasis shifts from what you've accomplished to what you *might* need to do. Regarding divisions, it's hard to say for sure, but my gut tells me areas heavily reliant on discretionary spending or those facing intense competition from smaller, nimbler players might be under more pressure. Stryker's strengths are undeniable, but even giants need to adapt to changing market dynamics and healthcare policy.